Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration-Reference-Cited by-同舟云学术

Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration

Published:2021-07-28 Issue:19 Volume:27 Page:5195-5212
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Anderson Kenneth C.,Auclair Daniel,Adam Stacey J.^ORCID,Agarwal Amit,Anderson Melissa^ORCID,Avet-Loiseau Hervé,Bustoros Mark^ORCID,Chapman Jessica^ORCID,Connors Dana E.^ORCID,Dash Ajeeta^ORCID,Di Bacco Alessandra^ORCID,Du Ling,Facon Thierry,Flores-Montero Juan^ORCID,Gay Francesca^ORCID,Ghobrial Irene M.,Gormley Nicole J.,Gupta Ira,Higley Howard,Hillengass Jens^ORCID,Kanapuru Bindu,Kazandjian Dickran,Kelloff Gary J.,Kirsch Ilan R.,Kremer Brandon,Landgren Ola^ORCID,Lightbody Elizabeth,Lomas Oliver C.^ORCID,Lonial Sagar,Mateos María-Victoria,Montes de Oca Rocio^ORCID,Mukundan Lata,Munshi Nikhil C.,O'Donnell Elizabeth K.,Orfao Alberto,Paiva Bruno,Patel Reshma,Pugh Trevor J.^ORCID,Ramasamy Karthik^ORCID,Ray Jill,Roshal Mikhail,Ross Jeremy A.,Sigman Caroline C.^ORCID,Thoren Katie L.^ORCID,Trudel Suzanne,Ulaner Gary,Valente Nancy,Weiss Brendan M.,Zamagni Elena,Kumar Shaji K.

Funder

Foundation for the National Institutes of Health

Multiple Myeloma Research Foundation

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Longitudinal genetically detectable minimal residual disease by fluorescence in situ hybridization confers a poor prognosis in myeloma;Therapeutic Advances in Medical Oncology;2024-01

2. Immunophenotypic assessment of clonal plasma cells and B-cells in bone marrow and blood in the diagnostic classification of early stage monoclonal gammopathies: an iSTOPMM study;Blood Cancer Journal;2023-12-11

3. Upfront or Deferred Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Triplet and Quadruplet Induction and Minimal Residual Disease/Risk-Adapted Therapy;Cancers;2023-12-05

4. Multiparametric Flow Cytometry in the Evaluation of Plasma Cell Proliferative Disorders: Current Paradigms for Clinical Practice;Clinical Lymphoma Myeloma and Leukemia;2023-11

5. Clinical factors associated with autologous stem cell transplantation outcomes in multiple myeloma: upfront transplant with MEL200 remains the standard of care;Annals of Hematology;2023-10-25